Drug Database
FL

flurbiprofen (Yakuban Tape)

✓ Approved

Kaken Pharmaceutical · PTGS1 · 小分子

什么是 flurbiprofen?

flurbiprofen 是一种小分子,由Kaken Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

商品名Yakuban Tape
公司Kaken Pharmaceutical
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Transdermal
状态Approved

作用机制

分子靶点

flurbiprofen 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

flurbiprofen 针对 5 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved
Injury, poisoning and procedural complicationsEpicondylitis✓ Approved
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Musculoskeletal and connective tissue disordersTendonitis✓ Approved

相关研究文献

PubMedAdvanced healthcare materials2026-11-17

From Transdermal Delivery to Immune Reprogramming: Intelligent Biomaterials for Precision Psoriasis Therapy.

Jiang Xue X, Lu Yang Y, Hu Zhuang Z, Wen Peng P et al.

Psoriasis is a chronic immune-mediated inflammatory disease that causes dysregulation of keratinocyte proliferation, IL-23/IL-17-driven immune activation, oxidative stress and impaired barrier function. Biologics and targeted small molecules have improved clinical results, but systemic administration and lack of lesion specificity limit precise, long-term control of the disease. This paper revises the concept of psoriasis therapy from transdermal drug delivery to intelligent immune microenvironment reprogramming. Programmable biomaterial platforms that can actively recognize pathological signals and achieve spatiotemporal control of drug release, immune cell targeting, gene regulation and tissue remodelling have been introduced. Recently, there have been many developments in stimuli-responsive hydrogels, microneedle-based gene editing, biomimetic nanoplatforms, extracellular matrix-inspired scaffolds, and image-guided theranostic systems that link disease mechanisms, material design and therapeutic functions in a unified framework. We have further put forward the idea of cytokine blockade as a network-level immune recalibration, enhanced penetration and lesion-specific adaptive regulation, and image-guided precise intervention over empirical treatment. The three main translation problems are lesion heterogeneity, controllable immune modulation and large-scale manufacturing and long-term safety. This review provides a plan for developing intelligent, personalized biomaterial-based therapies for personalized psoriasis management.

PMID 43040914
阅读全文 →
PubMedInternational journal of pharmaceutics2026-11-16

Transdermal delivery of cobimetinib via HPMC gel combining menthol and iontophoresis for locoregional melanoma treatment.

Jiang Changzhao C, Wang Zhixiong Z, Hu Jianling J, Wu Jialin J et al.

Orally administered cobimetinib (COBI), a selective MEK1/2 inhibitor is effective against melanoma but is associated with systemic adverse events. Herein, the HPMC-based gel combining menthol and iontophoresis was developed for locoregional transdermal delivery of COBI. Formulation was optimized via single-factor screening and an L9(33) orthogonal design. Optimized gels exhibited acceptable rheological properties and physical stability under stress conditions. In vitro permeation using excised rat abdominal skin revealed that 5% (w/w) menthol significantly enhanced COBI permeation, while iontophoresis was optimized at 3 h with 0.45% (w/w) NaCl. Based on the in vitro optimization, 0.8% (w/w) COBI loading was selected as the medium-dose candidate for subsequent in vivo efficacy evaluation (with 0.4% and 1.2% evaluated as low and high doses, respectively). In B16F10 cells, COBI combined with mild direct current showed greater inhibition of cell viability than either treatment alone. In tumor-bearing C57BL/6 mice, the optimized gelplus iontophoresis achieved achieved a tumor-weight inhibition rate of 98.2%, with histological findings suggesting increased tumor necrosis and reduced proliferation. At an equivalent dose, passive transdermal administration produced lower systemic exposure than oral dosing, whereas iontophoresis achieved comparable systemic exposure to passive delivery at half the nominal dose. In a separate mouse study, selected transdermal regimens exhibited higher tumor-to-plasma concentration ratios than oral administration at a single sampling time point. Collectively, this study demonstrates that the HPMC gel combining menthol and iontophoresis enables effective local tumor suppression.

PMID 43039121
阅读全文 →
PubMedACS biomaterials science & engineering2026-11-16

Barbed Dissolving Poly-γ-Glutamic Acid Microneedles for Reduced-Frequency Transdermal Levothyroxine Delivery in Hypothyroidism.

He Yan Y, Wang Panxia P, Wen Jiangyan J, Li Ying Y et al.

Hypothyroidism often requires lifelong thyroid hormone replacement, but oral levothyroxine (LT4) treatment depends on daily administration and gastrointestinal absorption. Here, we developed an LT4-loaded barbed dissolving microneedle patch based on poly-γ-glutamic acid (γ-PGA) (LT4@MN) for reduced-frequency transdermal delivery. LT4 was incorporated into the needle region, while the γ-PGA backing was prepared without the drug. The microneedles exhibited well-defined morphology, sufficient mechanical strength, moisture-responsive dissolution behavior, effective skin penetration to a depth of approximately 700 μm, and favorable cytocompatibility. In a total thyroidectomy-induced hypothyroid rat model, LT4@MN administered once every 6 days increased serum total thyroxine (TT4) from the hypothyroid baseline and maintained elevated TT4 levels across three consecutive treatment cycles. However, serum thyroid-stimulating hormone (TSH) did not show a clear sustained decrease during treatment. Repeated application caused no obvious local tissue damage or histopathological abnormalities in major organs. These findings support the feasibility of reduced-frequency transdermal LT4 delivery using barbed dissolving γ-PGA microneedles and highlight their potential as a minimally invasive alternative to daily oral administration.

PMID 43037648
阅读全文 →
PubMedInternational journal of pharmaceutics2026-11-16

Electrochemically assisted controlled-release study of the anticancer drug 5-fluorouracil by using fabrication of skin-simulating chip as a transdermal drug delivery model.

Badvi Hoda H, Alizadeh Naader N

The controlled release of cancer drugs is vital for minimizing side effects and ensuring the desired therapeutic outcomes. In this study, we developed conductive polymer coated on carbon felt (CF) as a soft pad to investigate the controlled-release of the anticancer drug 5-fluorouracil. This process utilizes the electrical properties of the conductive polymer, polypyrrole (PPy) which also responds to changes in pH. By applying various electrical potentials at different pH levels and temperatures, the pad can release different amounts of the drug over time. The drug release profile was continuously monitored in real time through a combination of spectrometry and electrochemical methods. The findings indicated that increasing the applied electrical potential significantly accelerated the rate of drug release. The release rate constants were obtained by fitting the data with the Avrami equation, while the activation parameters were determined using the Arrhenius and Eyring equations. This designed system allows for control of drug release from the prepared soft pad at a low potential of -0.6 V, making it ideal for clinical applications, particularly in transdermal delivery. Given that the 5-fluorouracil is an anti-skin cancer drug, a skin-simulating chip was design and fabricate to investigate its release and transdermal delivery. The findings confirmed the effectiveness of the soft pads in facilitating controlled drug release and delivery in different potentials.

PMID 43035168
阅读全文 →
PubMedClinical, cosmetic and investigational dermatology2026-11-16

Comprehensive Hair Loss Treatment: Bridging Drugs and Medical Devices.

Ren Xuebao X, Huang Yafei Y, Li Guorui G

Hair loss, a common clinical disorder, has become a public health issue affecting all ages. It not only impairs appearance but also impacts patients' mental health and quality of life. Traditional single-treatment approaches cannot meet patients' complex needs. Thus, constructing a comprehensive treatment system with the synergistic effects of pharmaceuticals and medical devices is a crucial development direction. Pharmacotherapy, including 5α-reductase inhibitors like finasteride and topical hair growth promoters like minoxidil, is the cornerstone of androgenetic alopecia treatment, but has challenges in clinical application. Medical devices and physical therapies, such as microneedling and dermal rollers, improve transdermal absorption of topical drugs and achieve synergistic effects. Hair transplantation surgery combined with postoperative pharmacological maintenance therapy forms a "reconstruction-maintenance" strategy. Comprehensive treatment emphasizes systematic interventions in multiple dimensions, like patients' lifestyle, mental stress, and scalp microecology, enhancing long-term efficacy and patient satisfaction, and driving the shift from single intervention to holistic health management. This paper elaborates on hair loss-related therapies to establish the concept of comprehensive treatment for hair loss.

PMID 43036742
阅读全文 →
PubMedACS biomaterials science & engineering2026-11-16

Curcumin-Loaded Zinc-Ginsenoside MOF Microneedles Attenuate Androgen-Induced Follicular Damage and Promote Hair Regrowth.

Gao Xinyu X, Zhu Yingying Y, Liu Yuansong Y, Zhang Xindan X et al.

Androgenetic alopecia (AGA) is the most prevalent form of hair loss worldwide, yet effective treatment remains challenging due to the limited skin permeability of conventional therapeutics and the systemic adverse effects of existing pharmacotherapies. Herein, we report a minimally invasive, dissolvable microneedle (MN) platform (Cur@ZnMOF/MN) that delivers curcumin (Cur) encapsulated within an all-bioactive ginsenoside Rg1-zinc metal-organic framework (ZnMOF) for localized pathological follicular microenvironment remodeling. The ZnMOF nanocarrier is constructed exclusively from zinc ions and ginsenoside Rg1, ensuring that each structural component actively contributes to therapeutic efficacy, while enabling sustained curcumin release. In vitro, Cur@ZnMOF effectively scavenges reactive oxygen species, suppresses dihydrotestosterone (DHT)-induced inflammatory cascades, and restores dermal papilla cell (DPC) viability and migratory function. Mechanistically, the platform attenuates DHT-triggered TGF-β inhibitory signaling, thereby reactivating the pro-regenerative Wnt/β-catenin pathway. In a murine AGA model, topical application of Cur@ZnMOF/MN significantly accelerated hair regrowth, increasing follicular depth, upregulating Ki67 and β-catenin expression, and promoting hair shaft elongation compared to monotherapy controls. By integrating targeted transdermal delivery with a fully bioactive nanotherapeutic system, this strategy offers a multi-target approach to reverse follicular miniaturization, providing a highly promising and clinically translatable paradigm for AGA management.

PMID 43038136
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多flurbiprofen